rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
4
|
pubmed:dateCreated |
2011-4-19
|
pubmed:abstractText |
Sorafenib has become the treatment standard for patients with advanced hepatocellular carcinoma (HCC). It is not clear whether patients with advanced liver function impairment (Child B) and patients undergoing additional locoregional therapy may tolerate treatment with sorafenib and benefit. We aimed to evaluate the tolerability and efficiency of sorafenib in patients with advanced HCC and different stages of liver cirrhosis, and in combination with locoregional therapy.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:issn |
1421-9867
|
pubmed:author |
|
pubmed:copyrightInfo |
Copyright © 2011 S. Karger AG, Basel.
|
pubmed:issnType |
Electronic
|
pubmed:volume |
83
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
275-82
|
pubmed:meshHeading |
pubmed-meshheading:21282952-Adolescent,
pubmed-meshheading:21282952-Adult,
pubmed-meshheading:21282952-Aged,
pubmed-meshheading:21282952-Aged, 80 and over,
pubmed-meshheading:21282952-Antineoplastic Agents,
pubmed-meshheading:21282952-Benzenesulfonates,
pubmed-meshheading:21282952-Carcinoma, Hepatocellular,
pubmed-meshheading:21282952-Cohort Studies,
pubmed-meshheading:21282952-Female,
pubmed-meshheading:21282952-Humans,
pubmed-meshheading:21282952-Liver Cirrhosis,
pubmed-meshheading:21282952-Liver Neoplasms,
pubmed-meshheading:21282952-Male,
pubmed-meshheading:21282952-Middle Aged,
pubmed-meshheading:21282952-Pyridines,
pubmed-meshheading:21282952-Treatment Outcome,
pubmed-meshheading:21282952-Young Adult
|
pubmed:year |
2011
|
pubmed:articleTitle |
Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis.
|
pubmed:affiliation |
Departments of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
|
pubmed:publicationType |
Journal Article
|